Sponsored by
Panzem Gets Orphan Drug Status for Glioblastoma Multiforme
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Entremed for their agent Panzem (2-methyoxyestradiol) for the treatment of glioblastoma multiforme (GBM). The designation of orphan drug status was based on in vitro studies that demonstrated anti-proliferative activity against glioma cell lines, and anti-tumor activity in in vivo studies involving a preclinical model of glioblastoma. Panzem has also previously been granted orphan drug status for multiple myeloma and ovarian cancer